Kevin Lobo - Stryker Chairman

SYK Stock  USD 328.45  2.95  0.91%   

Chairman

Mr. Kevin A. Lobo is Chairman of the Board, Chief Executive Officer of the Company. He was named Chairman of the Board in July 2014 and has served as Chief Executive Officer of the Company since 2012. He joined the Company as a Group President in April 2011. Prior thereto, he held leadership roles over eight years with Johnson Johnson, including president of Ethicon EndoSurgery. Mr. Lobo is also a director of ParkerHannifin Corporationrationration, a manufacturer of motion and control technologies and systems since 2021.
Age 59
Tenure 3 years
Address 1941 Stryker Way, Portage, MI, United States, 49002
Phone269 385 2600
Webhttps://www.stryker.com

Latest Insider Transactions

2023-11-17Disposed of 56483 shares @ 287.91View
Lobo global business and leadership experience across multiple industries, including healthcare, enables him to provide valuable insight to the Board regarding the Company operations and the strategic planning initiatives necessary to meet the demands of the changing environment. As the sole member of management on our Board, he provides management business perspectives and the necessary link to the Company daytoday operations.

Stryker Management Efficiency

The company has Return on Asset of 0.0723 % which means that on every $100 spent on assets, it made $0.0723 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1864 %, implying that it generated $0.1864 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.
The company has 12.99 B in debt with debt to equity (D/E) ratio of 0.88, which is OK given its current industry classification. Stryker has a current ratio of 1.96, which is typical for the industry and considered as normal. Debt can assist Stryker until it has trouble settling it off, either with new capital or with free cash flow. So, Stryker's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Stryker sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Stryker to invest in growth at high rates of return. When we think about Stryker's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

CHAIRMAN Age

Christopher CoccioSono Tek Corp
83
Stryker Corporation operates as a medical technology company. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan. Stryker Corp operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 46000 people. Stryker (SYK) is traded on New York Stock Exchange in USA. It is located in 1941 Stryker Way, Portage, MI, United States, 49002 and employs 52,000 people. Stryker is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Stryker Leadership Team

Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew Silvernail, Independent Director
Donald Payerle, President Replacement
Sherilyn McCoy, Independent Director
Lisa Tatum, Independent Director
Robert Cohen, CTO Replacement
Ronda Stryker, Independent Director
Preston Wells, Vice President - Investor Relations
Bradford Saar, President Medical
Spencer Stiles, Group President Orthopaedics and Spine
Andrew Pierce, Group Neurotechnology
William Berry, Principal Accounting Officer, Vice President, Corporate Controller
Allan Golston, Lead Independent Director
Dragana Bunjevac, Middle Europe
Stuart Silk, Middle Europe
Kevin Lobo, Chairman of the Board, President, Chief Executive Officer
Giovanni Caforio, Independent Director
Jason Beach, Vice Relations
Roch Doliveux, Independent Director
Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing
M Fink, Chief Human Resource Officer, Vice President
Mike Panos, North RD
Timothy Scannell, Group President of Medsurg and Neurotechnology
Robert Fletcher, Vice President Chief Legal Officer
Brian White, President Solutions
Dylan Crotty, President Instruments
Brent Ladd, President Endoscopy
Rajeev Suri, Independent Director
Alan Douville, Chief VP
Glenn Boehnlein, Chief Financial Officer, Vice President
J Pierce, Group President MedSurg and Neurotechnology
Viju Menon, Group President - Global Quality and Business Operations
Mary Brainerd, Independent Director
Srikant Datar, Independent Director
Maurice BenMayor, President Pacific

Stryker Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Stryker Investors Sentiment

The influence of Stryker's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Stryker. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Stryker's public news can be used to forecast risks associated with an investment in Stryker. The trend in average sentiment can be used to explain how an investor holding Stryker can time the market purely based on public headlines and social activities around Stryker. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Stryker's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Stryker's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Stryker's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Stryker.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Stryker in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Stryker's short interest history, or implied volatility extrapolated from Stryker options trading.

Currently Active Assets on Macroaxis

When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing.
For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Stryker Stock analysis

When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
CEOs Directory
Screen CEOs from public companies around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.331
Dividend Share
3.1
Earnings Share
8.77
Revenue Per Share
55.173
Quarterly Revenue Growth
0.097
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.